Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[89Zr]Zr-BI 754111 PET imaging in NSCLC and HNSCC
NCT03780725Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2019
- Primary completion
- Feb 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of miptenalimab in non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Standard Uptake Value in a 1ml Sphere Around Highest SUV Pixel at 144 hours. Started Jan 2019; status: terminated.
02
Drugs
miptenalimab
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03780725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03780725.